Vitamin D deficiency and co-morbidities in COVID-19 patients – A fatal relationship?
This is a update review (PDF free available) of the topic Vitamin D deficiency and co-morbidities in COVID-19 patients published in NFS Journal 20 (2020) 10–21
Here the conclusion
An inadequate supply of vitamin D has a variety of skeletal and nonskeletal effects. There is ample evidence that various non-communicable diseases (hypertension, diabetes, CVD, metabolic syndrome) are associated with low vitamin D plasma levels. These comorbidities, together with the often concomitant vitamin D deficiency, increase the risk of severe COVID-19 events. Much more attention should be paid to the importance of vitamin D status for the development and course of the disease. Particularly in the methods used to control the pandemic (lockdown), the skin's natural vitamin D synthesis is reduced when people have few opportunities to be exposed to the sun. The short halflives of the vitamin therefore make an increasing vitamin D deficiency more likely. Specific dietary advice, moderate supplementation or fortified foods can help prevent this deficiency. In the event of hospitalisation, the status should be urgently reviewed and, if possible, improved. In the meantime, 8 studies have started to test the effect of supplementing vitamin D in different dosages (up to 200,000 IU) on the course of the COVID-19 disease. The aim is to clarify whether supplementation with vitamin D in different dosages has an influence on the course of the disease or, in particular, on the immune response, or H.K. Biesalski NFS Journal 20 (2020) 10–21 17 whether it can prevent the development of ARDS or thromboses